Hematide

PALO ALTO, Calif., May 15, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Affymax, Inc. (Nasdaq: AFFY) today reported financial results for the first quarter ended March 31, 2007. The net loss for the first quarter of 2007 was $7.2 million compared to a net loss of $6.7 million for the first quarter of 2006. Affymax recognized revenue f...

PALO ALTO, Calif., May 07, 2007 (BUSINESS WIRE) -- Affymax, Inc. (Nasdaq:AFFY) today announced that Paul B. Cleveland, the company's chief financial officer and executive vice president, Corporate Development, will present at the Acumen BioFin 4th Annual Global Health Care Conference on Monday, May 14, 2007 at 4:20 p.m. in Monte Carlo. A live w...

PALO ALTO, Calif., Apr 24, 2007 (BUSINESS WIRE) -- Affymax, Inc. (Nasdaq: AFFY) today announced that Arlene M. Morris, the company's president and chief executive officer, will present at two upcoming healthcare conferences. Ms. Morris will present at the Morgan Stanley Global Healthcare Unplugged Conference on Wednesday, May 2, 2007 at 10:15 a.m. ...

PALO ALTO, Calif., Apr 23, 2007 (BUSINESS WIRE) -- Affymax, Inc. (Nasdaq:AFFY) today announced results to date from two separate Phase 2 clinical trials of Hematide(TM) in dialysis and non-dialysis chronic kidney disease (CKD) patients. The data showed that in treatment naive, non-dialysis patients Hematide could correct anemia when administered mo...

PALO ALTO, Calif. & OSAKA, Japan, Apr 18, 2007 (BUSINESS WIRE) -- Affymax, Inc. (Nasdaq: AFFY), a biopharmaceutical company, and Takeda Pharmaceutical Company Limited today announced that they were honored with the Allicense 2007 Breakthrough Alliance Award for their exclusive global agreement to develop and commercialize Hematide(TM), Affymax's le...

PALO ALTO, Calif., Apr 12, 2007 (BUSINESS WIRE) -- Affymax, Inc. (Nasdaq:AFFY) today announced that results available from its Phase 2 clinical trial of Hematide(TM) dosed monthly in dialysis patients were presented this week at the National Kidney Foundation (NKF) 2007 Spring Clinical Meeting. The results from this maintenance-switch trial in pati...

PALO ALTO, Calif., Apr 02, 2007 (BUSINESS WIRE) -- Affymax, Inc. (Nasdaq: AFFY) today reported financial results for the year ended December 31, 2006. The net loss for the year ended December 31, 2006 was $48.3 million compared to a net loss of $32.6 million for the year ended December 31, 2005. Affymax recognized revenue for the year ended Dec...

PALO ALTO, Calif., Mar 07, 2007 (BUSINESS WIRE) -- Affymax, Inc. (Nasdaq:AFFY) today announced that Arlene M. Morris, the company's president and chief executive officer, will present at the 27th Annual Cowen and Company Health Care Conference on Wednesday, March 14, 2007 at 8:00 a.m. Eastern Time in Boston. A live webcast of the presentation w...

PALO ALTO, Calif., Feb 28, 2007 (BUSINESS WIRE) -- Affymax, Inc. (Nasdaq:AFFY) today announced that Hironori Hozoji, a representative of the venture capital firm JAFCO Co., Ltd., resigned from its board of directors. "I would like to thank Hironori for his many contributions to Affymax during his tenure on our board," said Arlene Morris, presid...

PALO ALTO, Calif., Feb 05, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Affymax, Inc. (Nasdaq: AFFY), a biopharmaceutical company, today announced that Arlene M. Morris, the company's president and chief executive officer, will present at the 9th Annual BIO CEO & Investor Conference on Monday, February 12, at 2:00 p.m. Eastern Time at The...

PALO ALTO, Calif., Feb 01, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Affymax, Inc. (Nasdaq: AFFY), a biopharmaceutical company, today announced that it has received a $10 million development milestone payment from Takeda Pharmaceutical Company as part of the companies' exclusive global agreement to develop and commercialize Hematide(TM...

PALO ALTO, Calif., Dec 20, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Affymax, Inc. (Nasdaq: AFFY), a clinical-stage pharmaceutical company, today announced the completion of its initial public offering of 3.7 million shares of its common stock and the exercise by the underwriters of their option to purchase an additional 555,000 shares...

PALO ALTO, Calif., December 14, 2006 – Affymax, Inc. (Nasdaq: AFFY), a clinical-stage pharmaceutical company, today announced the pricing of its initial public offering of 3.7 million shares of common stock at $25.00 per share. All shares are being offered by Affymax. Affymax's common stock will trade on the Nasdaq Global Market under th...

PALO ALTO, Calif., December 11, 2006 – Affymax, Inc., a clinical-stage pharmaceutical company, today announced the presentation of results from an ongoing Phase 2, open-label, multicenter, dose-finding clinical trial of Hematide™ in anemic cancer patients receiving chemotherapy. Hematide, a novel peptide-based drug designed to stimulate ...

PALO ALTO, Calif., November 17, 2006 – Affymax, Inc. a clinical-stage pharmaceutical company, today announced the presentation of preclinical data on a Hematide™-related peptide at the American Society of Nephrology Renal Week 2006 in San Diego. Hematide, a novel peptide-based drug designed to stimulate the production of red blood cells,...

PALO ALTO, Calif., October 25, 2006 - Affymax, Inc. a clinical-stage pharmaceutical company, today announced the appointment of Grace U. Shin as vice president of legal affairs and corporate counsel. Ms. Shin, who has more than 15 years of experience as a corporate attorney, joins Affymax as a member of the senior management team."Grac...

PALO ALTO, Calif., October 6, 2006 - Affymax, Inc. a clinical-stage pharmaceutical company, today announced the appointment of Daniel K. Spiegelman to the Company's board of directors. Mr. Spiegelman is currently senior vice president and chief financial officer (CFO) of CV Therapeutics (Nasdaq: CVTX), a position he has held since 1999. ...

PALO ALTO, Calif., September 15, 2006 - Affymax, Inc. announced today the publication of clinical data from its Phase 1 trial of Hematide™ in the September 15 issue of the scientific journal Blood. The study results demonstrated that single doses of Hematide resulted in dose-dependent increases in circulating reticulocytes in normal healthy volunt...

PALO ALTO, Calif., July 28, 2006 - Affymax, Inc. announced today that it has filed a registration statement on Form S-1 with the Securities and Exchange Commission for a proposed initial public offering of shares of its common stock. All of the shares in the proposed offering are being sold by Affymax.The underwriters of the offering ...

PALO ALTO, Calif., July 27, 2006 - Affymax, Inc., a clinical-stage pharmaceutical company, today announced the appointment of Ted W. Love, M.D., to the Company's board of directors. Dr. Love is currently chairman and chief executive officer of Nuvelo, Inc. (Nasdaq: NUVO). "Ted Love is an experienced and highly-respected biotechnology i...